GlobeNewsWire · IMRX · November 12, 2026

Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients

Get the app for more

Explore stock news, insights and company research.